[
    [
        {
            "time": "2021-08-16",
            "original_text": "药明康德：于8月16日根据3亿美元可转换债券而转换及发行11.85万股H股",
            "features": {
                "keywords": [
                    "药明康德",
                    "可转换债券",
                    "H股",
                    "发行"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德：于8月16日根据3亿美元可转换债券而转换及发行11.85万股H股",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-09",
            "original_text": "西南证券：维持药明康德(603259.SH)“买入”评级 业绩高速增长 CDMO业务增速亮眼",
            "features": {
                "keywords": [
                    "药明康德",
                    "西南证券",
                    "买入评级",
                    "CDMO业务",
                    "业绩增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券：维持药明康德(603259.SH)“买入”评级 业绩高速增长 CDMO业务增速亮眼",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-13",
            "original_text": "A股融资融券日报：两融余额减少36.53亿元（8月13日）",
            "features": {
                "keywords": [
                    "两融余额",
                    "减少",
                    "A股"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "整体市场"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额减少36.53亿元（8月13日）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-13",
            "original_text": "大摩：维持药明康德(02359)“增持”评级 目标价升3.5%至207港元",
            "features": {
                "keywords": [
                    "药明康德",
                    "大摩",
                    "增持评级",
                    "目标价提升"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "大摩：维持药明康德(02359)“增持”评级 目标价升3.5%至207港元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-13",
            "original_text": "【行情】港股生物技术板块与药品股午后震荡走低，康龙化成跌超5%，昭衍新药与百济神州跌超3.4%，药明康德跌2.56%",
            "features": {
                "keywords": [
                    "港股",
                    "生物技术",
                    "药品股",
                    "震荡走低",
                    "药明康德"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【行情】港股生物技术板块与药品股午后震荡走低，康龙化成跌超5%，昭衍新药与百济神州跌超3.4%，药明康德跌2.56%",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]